Recently Featured

Government Accountability Office Calls for FDA to Finalize Advisory Committee Conflict of Interest Guidance

April 9, 2026
The Government Accountability Office (GAO) has highlighted significant shortcomings in the Food and Drug Administration’s (FDA) management of advisory committee member financial conflicts of interest. According to the GAO’s review, the FDA has not adequately communicated its criteria for determining whether committee members should participate in meetings, a situation that has persisted for over a…

Pfizer, BioNTech to Pause COVID Vaccine Study Due to Low Enrollment

April 8, 2026
Pfizer and BioNTech have announced the suspension of their COVID-19 vaccine study, citing insufficient enrollment as the primary reason. This decision comes as part of a post-marketing commitment mandated by FDA Commissioner Martin Makary, which was established last year for all approved COVID vaccines. The low enrollment figures raise concerns about the ongoing engagement and…

Cancer Vaccine Design Gets Personal

April 8, 2026
The landscape of cancer immunotherapies is evolving rapidly, with drugmakers exploring various technologies beyond the popular peptide and mRNA vaccines encapsulated in lipid nanoparticles. These emerging platforms, many of which are nearing clinical application, aim to enhance therapeutic responses, improve safety profiles, and streamline manufacturing processes. Notably, approaches utilizing viral, bacterial, and synthetic vectors, alongside…

FDA Aims to Expedite New Drug Trials to Compete with China

April 8, 2026
The FDA plans to reduce the amount of data required to initiate new drug trials in the United States, focusing primarily on safety-related information, as announced by FDA Commissioner Marty Makary. This strategic shift is designed to streamline the approval process and enhance the competitiveness of U.S. pharmaceutical companies in the global market, particularly against…

Ongoing Cases